Market Overview

$3.4 Bn Liquid Biopsy Market to 2024 - Global Analysis by Cancer, Product, Circulating Biomarkers, Clinical Application, Regions, and Companies -


The "Liquid
Biopsy Market, Global Analysis by Cancer, Product, Circulating
Biomarkers, Clinical Application, Regions, and Companies"

report has been added to's

Liquid Biopsy Market is projected to exceed US$ 3.4 Billion by the year
2024, witnessing the worldwide increasing prevalence of cancer and
raising awareness regarding the minimal invasive liquid biopsy
technology across the world.

Today, liquid biopsy has paved the road of cancer diagnosis and
treatment by offering a complete treatment response in real time without
the need of serial traditional (solid-tissue) biopsies.

Today, the population across the globe is growing and aging and so is
the global burden of cancer; it is estimated that by the year 2030, the
global cancer burden will reach nearly 21.7 Million new cancer cases and
be around 13 Million cancer deaths. It is also expected that the low and
middle income countries accounts for 60% of the cancer deaths due to the
lack of medical resources and proper healthcare systems.

The cases of cancer increases very rapidly around the world owing to the
adoption of unhealthy lifestyles and behaviors such as smoking, poor
diet, physical inactivity etc. These rising cases of cancer will drive
the liquid biopsy market to thrive in the coming years. As liquid biopsy
is a simple and non-invasive technique it enables physicians to discover
a range of information about patient's tumor and provide clues about the
treatment that a patient's needs.

All the 9 Companies Studied in the Report have been Studied from
3 Points

  • Company Overview
  • Product Portfolio
  • Financial Insight

This market research report provides a complete analysis of the Liquid
Biopsy Market, Growth Drivers, Challenges, and their projections for the
upcoming years.

By Cancer

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Others

By Product

  • Kits & Consumables
  • Instruments
  • Services

By Circulating Biomarkers

  • Circulating Tumor Cells (CTCs)
  • Circulating Tumor DNA (ctDNA)
  • Exosomes

By Sample

  • Plasma/Serum
  • Urine
  • Others

By Clinical Application

  • Monitoring
  • Prognosis
  • Theranostics
  • Screening

By Companies

  • Thermo Fisher Scientific Inc.
  • Roche Diagnostics
  • Bio-Rad Laboratories Inc.
  • Biocept Inc.
  • Biocartis
  • Myriad Genetics, Inc.
  • Genomic Health
  • NeoGenomics Laboratories
  • Qiagen

For more information about this report visit

View Comments and Join the Discussion!